RxDoctor Payments Data

Meenal Shah, MD

Nephrology · Tracy, CANPI 1346443991

Payments from drug & device makers

$545in general payments, 2019–2025

Across 14 payments — averaging $38.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$193
  • Edwards Lifesciences$139
  • AstraZeneca$93
  • AbbVie$34
  • Baxter Healthcare$29
  • Vifor Pharma, Inc.$24
  • plus $34 from 2 others

What the payments were for

  • Food & beverage$52196%
  • Education$244%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$545 in reported general payments places this provider in the 35th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$366,999
Medicare patients
675
Services billed
2,501

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XphozahTenapanor Hcl26$81,275
VeltassaPatiromer Calcium Sorbitex25$47,852
FarxigaDapagliflozin Propanediol36$46,056
JardianceEmpagliflozin33$45,198
VelphoroSucroferric Oxyhydroxide15$23,166
Sevelamer Carbonate73$17,434
LokelmaSodium Zirconium Cyclosilicate15$17,020
Cinacalcet Hcl53$16,374
ProcritEpoetin Alfa18$14,668
SpsSodium Polystyrene Sulfon/Sorb14$10,280
Lanthanum Carbonate11$10,193
Calcium Acetate60$8,723
Calcitriol271$4,503
Hydralazine Hcl139$2,551
Furosemide178$1,369

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$93$63,07751 claims
Johnson & JohnsonProcrit$22$14,66818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,341 nephrology providers in California.

Other nephrology in Tracy

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →